VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCABusiness Wire • 09/13/24
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New YorkGlobeNewsWire • 09/04/24
Verrica Pharmaceuticals Inc. (VRCA) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/14/24
Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Patients with Basal Cell CarcinomaGlobeNewsWire • 08/14/24
Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP-315 for the Treatment of Basal Cell Carcinoma on August 14, 2024GlobeNewsWire • 08/06/24
Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.GlobeNewsWire • 07/01/24
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New YorkGlobeNewsWire • 05/30/24
Verrica Pharmaceuticals Announces Amendment to Company's Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common WartsGlobeNewsWire • 05/15/24
Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/13/24
Verrica Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 13, 2024GlobeNewsWire • 05/08/24
Verrica Pharmaceuticals (VRCA) Moves 7.4% Higher: Will This Strength Last?Zacks Investment Research • 05/06/24
Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare ConferenceGlobeNewsWire • 04/02/24
Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDAGlobeNewsWire • 03/26/24
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial ResultsGlobeNewsWire • 02/29/24
Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare ConferenceGlobeNewsWire • 02/27/24
Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024GlobeNewsWire • 02/22/24
Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair CompetitionGlobeNewsWire • 02/05/24
Verrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH™ from Centers for Medicare and Medicaid ServicesGlobeNewsWire • 01/29/24